Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects
Condition: Healthy
Intervention: BI 1026706; Itraconazole
Intervention description: Single dose of BI 1026706 on Day 1; 7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
Intervention MeSH terms: Itraconazole
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 16.0
Sex: Male
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The primary objective of this trial is to investigate the effect of multiple doses of
      itraconazole on the pharmacokinetics of BI 1026706 given as single dose. The assessment of
      safety and tolerability of BI 1026706 is an additional objective of this trial. Furthermore,
      the pharmacokinetics of the metabolite BI 1072668 will be explored.
    

Eligibility criteria:

        Inclusion criteria:

          -  Healthy male subjects according to the investigators assessment, based on a complete
             medical history including a physical examination, vital signs (BP, PR), 12-lead ECG,
             and clinical laboratory tests

          -  Age of 18 to 55 years (incl.)

          -  BMI of 18.5 to 29.9 kg/m2 (incl.)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

        Exclusion criteria:

          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from
             normal and judged as clinically relevant by the investigator

          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
             range of 50 to 90 bpm

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          -  Any evidence of a concomitant disease judged as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract that could interfere with the pharmacokinetics
             of the trial medication (except appendectomy and simple hernia repair)

          -  Diseases of the central nervous system (such as epilepsy), other relevant neurological
             or psychiatric disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy or hypersensitivity (including allergy to the trial
             medication or its excipients)

          -  Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10
             half-lives of the respective drug prior to administration of trial medication

          -  Within 10 days prior to administration of trial medication, use of drugs that might
             reasonably influence the results of the trial or that might prolong the QT/QTc
             interval

          -  Participation in another trial where an investigational drug has been administered
             within 60 days prior to planned administration of trial medication

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

          -  Inability to refrain from smoking during in-house confinement at trial site

          -  Alcohol abuse (consumption of more than 30 g per day)

          -  Drug abuse or positive drug screening

          -  Blood donation of more than 100 mL within 30 days prior to administration of trial
             medication or intended donation during the trial

          -  Intention to perform excessive physical activities within one week prior to
             administration of trial medication or during the trial

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are
             repeatedly greater than 450 ms) or any other relevant ECG finding at screening

          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,
             hypokalaemia, or family history of Long QT Syndrome)

          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,
             because the subject is considered not able to understand and comply with study
             requirements, or because he has a condition that would not allow safe participation in
             the study

        In addition, the following trial-specific exclusion criteria apply:

          -  Liver enzyme (ALT, AST, GGT) values above upper limit of normal at the screening
             examination

          -  Galactose intolerance, lactase deficiency, or glucose/galactose malabsorption